Medical Developments share price leaps 5% on FY22 revenue boost

The company said sales continued to be disrupted in FY22 due to the impacts from COVID.

| More on:
A doctor in a white coat with a stethoscope around his neck stands in the hallway of a hospital deep in concentration over a tablet device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Medical Developments share price gains on FY22 results
  • Underlying revenue increased by 37% year over year
  • The company forecasts strong growth in its French markets

The Medical Developments International Ltd (ASX: MVP) share price is up 4.6% as we head into the lunch hour.

Medical Developments shares closed yesterday at $1.85 and are currently trading for $1.93.

The ASX healthcare company, focused on emergency pain relief and respiratory products, released its full-year results for the 12 months ending 30 June (FY22) this morning.

Here are the highlights.

Medical Developments share price gains on revenue boost

  • Underlying revenue of $22.4 million, up 37% from FY21
  • Underlying earnings before interest and taxes (EBIT) came in at a loss of $14.7 million compared to a $10.1 million EBIT loss the prior year
  • Net loss after tax of $12.4 million, a slight improvement on the $12.2 million loss from FY21
  • No dividend declared.

What else happened during the year?

Medical Developments was able to lift its FY22 revenue despite ongoing disruption to sales from COVID restrictions throughout most of the 12 months. Those restrictions hit sales particularly hard in France, where the company is targeting significant growth.

Management said the fall in underlying EBIT, down $4.6 million from FY21, reflected that it's currently in the investment phase of its growth strategy.

As at 30 June the company had $20.4 million in cash. Adding in the $28.5 million proceeds it received from the capital raising this month, it reported a current proforma cash position of $49 million.

Revenue from Medical Developments' pain medication, Penthrox, was up 29% from FY21, driven by higher volumes. The company is working to accelerate sales of Penthrox in global markets, establishing a European regional team and an in-market sales team in France.

It also signed a distribution agreement with Paladin Labs in Canada, with supply to commence in FY23.

And in the United States, the Food and Drug Administration (FDA) lifted its clinical hold on Penthrox unconditionally, opening the door to commencing the Phase III study.

What did management say?

Commenting on the results that look to be lifting the Medical Developments share price today, CEO Brent MacGregor said:

We have delivered strong revenue growth against a challenging backdrop and have made significant progress in transitioning the Company to support direct sales in key markets, including building the leadership and functional capability to deliver our growth aspirations…

Our earnings reflect the investments we are making to build capability to execute our strategy, including a direct sales team in France, and enhanced leadership and functional teams. We will deliver leverage from these investments as we drive penetration and increase volumes.

What's next?

While not giving specific guidance, Medical Developments said it expects to deliver "strong revenue growth" in FY23. It aims to achieve this with significant growth in the French market along with growth in its respiratory segment driven by demand in the US.

"We remain confident that our pivot to direct sales in key markets will accelerate the growth of Penthrox and deliver significant long-term shareholder value," MacGregor said.

Medical Developments share price snapshot

Despite today's lift and a big run higher in June, the Medical Developments share price remains down 61% in 2022. That compares to a year-to-date loss of 7% posted by the All Ordinaries Index (ASX: XAO).

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Miner looking at a tablet.
Earnings Results

Rio Tinto share price on watch following FY 2023 earnings miss

Rio Tinto's iron ore operations were on form in 2023. It's a shame the rest of the business wasn't.

Read more »

Man with rocket wings which have flames coming out of them.
Earnings Results

4 All Ords ASX dividend shares going gangbusters on results

All Ords investors are sending these ASX dividend shares soaring on the back of their earnings results.

Read more »

Man waiting for his flight and looking at his phone.
Earnings Results

Corporate Travel share price plunges 18% despite tripling net profits

An explosion in earnings is taking a backseat to changes in Corporate Travel Management's full-year forecasts.

Read more »

happy woman throws arms in the air
Bank Shares

NAB shares hit 52-week high on first-quarter earnings beat

NAB appears on track to at least deliver on first-half expectations.

Read more »

A man wearing a shirt, tie and hard hat sits in an office and marks dates in his diary.
Earnings Results

Santos share price slips on 42% profit drop in FY23 result

Profits come back down to Earth in FY23.

Read more »

a man sits on a ridge high above a large city full of high rise buildings as though he is thinking, contemplating the vista below.
REITs

Here are 4 ASX 200 REITs results catching the eye on Wednesday

A mixed set of results have been announced by these property companies.

Read more »

Three analysts look at tech options on a wall screen
Earnings Results

WiseTech share price leaps 8% today as revenues surge

ASX 200 investors are bidding up the WiseTech share price today.

Read more »

Two parents and two children happily eat pizza in their kitchen as a top broker predicts a 46% upside for the Domino's share price
Earnings Results

Domino's share price charges higher on improving outlook

Here's how this struggling pizza chain operator performed during the first half.

Read more »